Samer Mouksassi
@poppkpd
Pharmacist, Pharmacometrician,
Drug Development, Biostatistician, Data Scientist, Visualizations,
R packages developer, Global Health
Assistant Professor
ID: 134519416
18-04-2010 17:12:59
1,1K Tweet
409 Followers
580 Following
A commentary on establishing a local centre of excellence for research and training in pharmacometrics: Lessons from the pharmacometrics Africa–Uganda chapter - Najjemba - 2023 - British Journal of Clinical Pharmacology - Wiley Online Library bpspubs.onlinelibrary.wiley.com/doi/10.1111/bc…
While preparing two new courses for Posit PBC's #positconf2023 in #Chicago, I've also updated the 2-day #ggplot2 workshop from last year's conf to use the same style 💅 Slides, exercises, solutions, and more—available here 👉 rstudio-conf-2022.github.io/ggplot2-graphi… #rstats #tidyverse #dataviz
Just 2 days to our symposium discussing synergies among different disciplines that use #Mathematics and #modeling to benefit #healthcare. I’m really looking forward to hearing our esteemed panel as they are guided by Catriona Waitt. Visit pmxafrica.org/cmms-2023/ for more details
Where do quantum physics, pharmacokinetic modelling, health economics and agricultural science? We found many exciting commonalities at the PMX Africa Data School cross disciplinary mathematical modelling and simulation symposium this morning. Francesco Petruccione
#DigitalHealthAfrica2024 Samer Mouksassi gives a clear overview of how PK modelling has developed since 1977 to now be able to inform precise dosing for clinically complex individuals. Further development of #AI alongside these approaches should help streamline clinical decision making
MHRAgovuk Ojara williams Francis Simon Peter Asiimwe🌍 🇺🇬 Karleen Gribble Breastfeeding For Doctors British Journal of Clinical Pharmacology (BJCP) British Pharmacological Society Charles Whalley💊📑 @Pharmaforkids @MHRAmedicines Also delightful to see Physiologically Based Pharmacokinetic Modelling getting a specific mention by Dame June Raines in her powerful call to action. Shakir Atoyebi Adeniyi Olagunju Joshua Kiptoo British Journal of Clinical Pharmacology (BJCP) #AtTheEquatorUG Project MADAM
James C Meyer I’m seeing less and less appropriateness of time-to-event analysis as patient outcomes are more complex and rich than that (including up and down responses over time), so I’m using Markov state transition models more. But for causality I refer to experts in g-estimation.
Really excellent work here! Random forest and XGBoost are overused, overhyped, and likely lead to worse decision making than if not used. That these are to facilitate “precision medicine” is a misunderstanding of the techniques and curse of dimensionality Roger Borràs Frank Harrell